Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Early lung cancer marker shows promise:

This article was originally published in Clinica

Executive Summary

A peptide in blood or sputum could provide a sensitive marker for the early diagnosis of lung cancer. Magnus von Knebel Doeberitz of the University of Heidelberg in Germany, and colleagues used a reverse transcriptase PCR test to study 175 patients suspected of having lung cancer. They found that preprogastrin-releasing peptide was present in 50% of blood samples and 22% of sputum samples from small-cell lung cancer patients. The blood test also identified 27% of non-small-cell lung cancer patients. The findings appear in the International Journal of Cancer (April).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT070965

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel